Drug intelligence / Profile preview

NAL2766

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NAL2766 is a nicotine mini-lozenge formulation developed by NAL Pharmaceutical Group for smoking cessation. As a nicotine replacement therapy (NRT), it acts as an agonist at nicotinic acetylcholine receptors (nAChRs) in the central nervous system, helping to alleviate withdrawal symptoms and reduce cravings in individuals attempting to quit smoking. The product is designed as an over-the-counter (OTC) oral lozenge and is currently in the preclinical or early development phase.

Other names: Nicotine Mini-Lozengenicotine

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on NAL2766.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL2766.

Explore the full profile